Last reviewed · How we verify
NCT06858709
Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy
NA trial testing True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatment in Chemotherapy-induced Peripheral Neuropathy (CIPN) in 150 participants. Currently enrolling.
15 January 2027
Quick facts
| Lead sponsor | Zhongnan Hospital |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 20 March 2025 |
| Primary completion | 15 January 2027 |
| Estimated completion | 30 March 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- True acupuncture + standard anti chemotherapy-induced peripheral neuropathy treatment
- Sham acupuncture +standard anti chemotherapy-induced peripheral neuropathy treatment
Conditions studied
- Chemotherapy-induced Peripheral Neuropathy (CIPN) — all drugs for Chemotherapy-induced Peripheral Neuropathy (CIPN) →
- Cancer — all drugs for Cancer →
Sponsor
Zhongnan Hospital
Who can join
18 and older, any sex, with Chemotherapy-induced Peripheral Neuropathy (CIPN) or Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is being done to evaluate the potential benefits of using electroacupuncture to reduce the severity of chemotherapy-induced peripheral neuropathy for patients with peripheral neuropathy after chemotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06858709
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chemotherapy-induced Peripheral Neuropathy (CIPN)
Currently open trials in the same condition.
- NCT07377279 — Acupuncture and Compression for the Prevention of CIPN in Breast Cancer Patients · NA · recruiting
- NCT07009717 — Relationship Between Great Toe Strength And Symptoms of Chemotherapy-Induced Peripheral Neuropathy (CIPN) · recruiting
Other Zhongnan Hospital trials
Trials by the same sponsor.
- NCT07515963 — FULIRI Plus Targeted Therapy for First-line Conversion Therapy of Colorectal Cancer Liver Metastases. · Phase 2 · not yet recruiting
- NCT07420036 — An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, · EARLY_PHASE1 · not yet recruiting
- NCT07453966 — Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mec · NA · recruiting
- NCT07363330 — A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer · Phase 2 · not yet recruiting
- NCT07460258 — A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06858709 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhongnan Hospital
- Last refreshed: 20 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06858709.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing